Combating Antibiotic Resistance Through the Health
The Health Impact Fund (Hollis & Pogge 2008) is an innovative financing mechanism for global drug discovery and dissemination, separating the recovery of sunk R&D costs from the market price of the drug, also known as de-linkage. Aaron Kesselheim and Kevin Outterson have recently proposed a mechanism to reimburse companies for antibiotics according to their social value, but conditioned on achieving conservation goals to limit resistance (Kesselheim & Outterson 2010, 2011). This paper will explore whether this antibiotic resistance pay-for-performance proposal can be adapted to the framework of the Health Impact Fund. If these proposals can be meshed, then antibiotics might be an interesting therapeutic class for a test of the Health Impact Fund.
Keywords: health impact, antibiotic, resistance, pay-for-performanceWorking Paper Series
Size: 440 KB
Adobe Acrobat Reader v3.01 or greater is required to view this paper.
Outterson, Kevin, Pogge, Thomas and Hollis, Aidan, Combating Antibiotic Resistance Through the Health Impact Fund (June 18, 2011). Boston Univ. School of Law, Law and Economics Research Paper, No. 11-30 (June 21, 2011). Available at SSRN: http://ssrn.com/abstract=1866768.
Email address: email@example.com